Existing diagnosis and treatment of Alzheimer’s and Parkinson’s disease occur when the disease has already progressed to a relatively advanced stage. egSEQ Amplicon panels offer clinicians and researchers a highly specific and cost-effective screening and research solution, with low sample input requirements and a simple workflow.
For researchers part of the UK's largest study on neurodegenerative diseases, egSEQ Amplicon panels provide a set of tools to examine genetic variants related to the brain with clinical accuracy on patients suffering from Alzheimer’s and Parkinson’s, which could represent a major step forwards in our understanding of these conditions that impact millions of people worldwide.'
Related Links:
